Sugi Predict

Sugi Predict / Compounds / SCHEMBL570801

SCHEMBL570801

SCHEMBL570801

CC(C)(C)OC(=O)NC1CC(=O)C1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.54
▸ NFKB1 P19838 4/20 0.53
▸ NFKB2 Q00653 4/20 0.53
▸ RELA Q04206 4/20 0.53
▸ BTK Q06187 1/20 0.51
▸ EPHX2 P34913 1/20 0.48
▸ CTSK P43235 2/20 0.47
▸ KDM1A O60341 2/20 0.44
▸ MAOB P27338 1/20 0.44
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ EPHX1 P07099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31246142 0.92 BTK (0.53) GAANFKB1NFKB2RELABTK
SCHEMBL1988919 0.86 NFKB1 (0.54) GAANFKB1NFKB2RELABTK
SCHEMBL8320677 0.85 CTSK (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL30073691 0.85 BTK (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL720530 0.85 CTSK (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL720531 0.85 CTSK (0.50) GAANFKB1NFKB2RELABTK
SCHEMBL25190566 0.85 BTK (0.61) GAANFKB1NFKB2RELABTK
Ethoxycarbonyl Group SCHEMBL28252011 0.84 GAA (0.43) GAANFKB1NFKB2RELABTK
SCHEMBL30073679 0.84 NFKB1 (0.53) GAANFKB1NFKB2RELABTK
SCHEMBL6335706 0.84 NFKB1 (0.53) GAANFKB1NFKB2RELABTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111848423-B Preparation method of tert-butyl 3-oxocyclobutylcarbamate 尚科生物医药（上海）有限公司 2022-10-14 — — CN claimed
CN-111848423-A Preparation method of tert-butyl 3-oxocyclobutylcarbamate 尚科生物医药（上海）有限公司 2020-10-30 — — CN claimed
US-12617759-B2 Modifier of four-membered ring derivative, preparation method and application thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2026-05-05 — — US disclosed
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 — — US disclosed
EP-3985001-B1 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER SERVIER LAB (FR) 2026-04-29 — — EP disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
EP-4178620-B1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-01 — — EP disclosed
US-20260085067-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF BOUNDLESS BIO INC (US) 2026-03-26 — — US disclosed
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 — — US disclosed
US-12583862-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2026-03-24 — — US disclosed
EP-3558298-B1 ANTIDIABETIC SPIROCHROMAN COMPOUNDS MERCK SHARP & DOHME LLC (US) 2026-03-11 — — EP disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 — — WO disclosed
US-7511062-B2 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors SCHERING CORPORATION (US) 2009-03-31 — — US disclosed
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-12-04 — — US disclosed
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-12-04 — — US disclosed
WO-2008124821-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-10-16 — — WO disclosed
WO-2008077551-A1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 — — WO disclosed
US-5567726-A SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS MERCK, SHARP & DOHME LTD. (GB) 1996-10-22 — — US disclosed
EP-0651749-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1995-05-10 — — EP disclosed
WO-1994002477-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ALG8, NRDC, MRPL21 GAA 100/4885NFKB1 485/4885NFKB2 1586/4885
US-20260085067-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF RRM1, RRM2B, RRM2 GAA 4081/4885NFKB1 4221/4885NFKB2 3981/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 GAA 3879/4885NFKB1 2322/4885NFKB2 1230/4885
US-12583862-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway BTK, PSMB2, PSME3 GAA 1572/4885NFKB1 449/4885NFKB2 417/4885
US-12617759-B2 Modifier of four-membered ring derivative, preparation method and application thereof CHRNA6, HTR6, GRM6 GAA 3182/4885NFKB1 3790/4885NFKB2 3880/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 GAA 2139/4885NFKB1 2177/4885NFKB2 1304/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 GAA 4247/4885NFKB1 1949/4885NFKB2 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.